NASDAQ:CLXT

Calyxt (CLXT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$6.01
$7.77
50-Day Range
$6.30
$31.50
52-Week Range
$1.25
$7.77
Volume
254,056 shs
Average Volume
139,308 shs
Market Capitalization
$31.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CLXT stock logo

About Calyxt Stock (NASDAQ:CLXT)

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.

CLXT Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Calyxt Completes One-for-Ten Reverse Stock Split
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Why Is Calyxt (CLXT) Stock Up 140% Today?
Calyxt, Inc. (NASDAQ: CLXT)
Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates
See More Headlines
Receive CLXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calyxt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2023
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:CLXT
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

Net Income
$-16,890,000.00
Net Margins
-9,979.64%
Pretax Margin
-9,979.64%

Debt

Sales & Book Value

Annual Sales
$160,000.00
Book Value
$0.54 per share

Miscellaneous

Free Float
4,865,000
Market Cap
$31.31 million
Optionable
Not Optionable
Beta
1.98
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives


CLXT Stock Analysis - Frequently Asked Questions

How were Calyxt's earnings last quarter?

Calyxt, Inc. (NASDAQ:CLXT) released its quarterly earnings data on Monday, May, 1st. The company reported ($5.45) earnings per share for the quarter, missing analysts' consensus estimates of ($3.00) by $2.45. The company had revenue of $0.04 million for the quarter. Calyxt had a negative trailing twelve-month return on equity of 259.69% and a negative net margin of 9,979.64%.

When did Calyxt's stock split?

Calyxt's stock reverse split before market open on Thursday, June 1st 2023. The 1-5 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Calyxt own?
When did Calyxt IPO?

Calyxt (CLXT) raised $101 million in an IPO on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities served as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

This page (NASDAQ:CLXT) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners